Navigation Links
Epothilone in Medical News

Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma

...upportive trial in patients with less advanced disease. Kosan's Hsp90 and epothilone Clinical Programs on Track for 2008 Kosan's TIME registration program is ...ancer who have not previously been treated with trastuzumab. Kosan's lead epothilone clinical candidate, KOS-1584, has demonstrated promising antitumor activity...

Study Findings Could Help In Developing A Better Drug Delivery System

...hat is in phase I studies. Endocyte has licensed its vitamin-targeting technology to Bristol-Myers Squibb to target Bristol-Myers Squibb's proprietary epothilone cancer chemotherapeutic agents. Source-Eurekalert VI ...
Epothilone in Medical Technology

Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer

HAYWARD, Calif., April 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that the Phase 2 trial of epothilone KOS-1584 in patients with non-small cell lung cancer has been initiated. The Phase 2 trial is an open-label, multi-center, monotherapy study ...

Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting

HAYWARD, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) presented updated data today from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated antitumor activity and tolerability in patients...

Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR

HAYWARD, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated today presented preclinical data on KOS-1803, a next-generation epothilone, showing a high level of antitumor activity and a favorable pharmacokinetic and safety profile in a broad range of in vitro tests and ...

Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated promising antitumor activity and tolerability in patients with solid tumors....

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

...atic breast cancer in combination with Herceptin(R) (trastuzumab). KOS-1584 epothilone product candidate is in a Phase 2 clinical trial in patients with non-small...s; Kosan' dependence on it license with Bristol-Myers Squibb to develop its epothilone products in order for Kosan to receive milestones or royalties, Kosan's dep...

Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

...Company's clinical and preclinical pipeline, including its Hsp90 inhibitor, epothilone and nuclear export inhibitor programs, at the 2007 Annual Meeting of the Am...S-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercial...

Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR

...lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. For additional information on Kosan Biosciences, pleas...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

...lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. For additional information on Kosan Biosciences, pleas...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

...lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. For additional information on Kosan Biosciences, pleas...

Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO

...lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. For additional information on Kosan Biosciences, pleas...
Epothilone in Biological Technology

Kosan to Reacquire Epothilone Program From Roche

Kosan to Commence Phase 2 Clinical Program for KOS-1584 HAYWARD, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that Roche and Kosan are concluding their epothilone development and commercialization collaboration. The collabora...

FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer

PRINCETON, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of IXEMPRA(TM) (ixabepilone) as monotherapy for the treatment of patients with metastatic or locally advanced brea...

Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer

...arkets and her work with a broad range of compound classes and tumor types will be of significant value to Kosan as we advance our Hsp90 inhibitor and epothilone programs through later stages of development," said Helen S. Kim, Kosan's President and Chief Executive Officer. "Recruiting an experienced and accomp...

Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs

...rams, tanespimycin in multiple myeloma and in metastatic breast cancer, and epothilone KOS-1584 in non-small lung cancer. The restructuring will primarily affect ...pany's reputation as a leader in polyketide technology as well as Hsp90 and epothilone drug discovery. We believe that this restructuring will strengthen our abil...

Kosan Announces Senior Management Changes and Clinical Portfolio Priorities

...loma and in metastatic breast cancer, and its lead epothilone candidate, KOS-1584, in non-small cell lung cancer...herapy beginning in late 2008 and early 2009. -- epothilone KOS-1584 is a key asset in Kosan's pipeline. Kosan...hanisms. With the recent FDA approval of the first epothilone (BMS' ixabepilone), the epothilone class has gaine...

Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook

...ter is primarily due to increased clinical costs in the Hsp90 inhibitor and epothilone programs, including costs associated with the initiation of the clinical tr...espimycin metastatic breast cancer clinical program, and the development of epothilone KOS-1584, which is entering Phase 2 in non-small cell lung cancer. We belie...

Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer

...on and sustainability of multiple partnering arrangements and license agreements with third parties, including with respect to its Hsp90 inhibitor and epothilone programs; Kosan's need for additional financing; Kosan's ability to obtain valid and enforceable patents covering its product candidates; Kosan's depe...

Kosan Announces Third Quarter 2007 Financial Results

...gram in multiple myeloma and investment in Kosan's epothilone program, including KOS-1584 process development wh...nnounced that Roche and Kosan are concluding their epothilone development and commercialization collaboration. T...which Kosan will reacquire worldwide rights to its epothilone program and have full control of clinical developm...
Other Tags
(Date:1/22/2015)... (PRWEB) January 23, 2015 The U.S. ... R.Ph., DICVP, Director of Clinical Pharmacy Services at North ... the recipient of the 2015 Beal Award for Distinguished ... USP has relied on the contributions of volunteer experts ...
(Date:1/22/2015)... 2015 Gabe’s Chemo Duck Program is pleased to ... app ever created for kids with cancer. The Chemo Duck App, ... is filled with enjoyable games to help children of all ages ... app helps to keep kids entertained, educated and at ease while ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
(Date:1/22/2015)... , Europe,s most prestigious innovation prize ... present a video retrospective of the most exciting and innovative nominations  ... and Sophie Wilson   A different theme ... Starting on 22 January 2015 on   http://www.epo.org/european-inventor   ...
(Date:12/24/2014)... launch in December 2014, the 1U™ app has ... to remember their usernames and passwords through replacing the antiquated ... assist people who have struggled to remember usernames and passwords, ... focuses on redefining identity, announced today that it is offering ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... http://photos.prnewswire.com/prnh/20130307/600769 ... introduced the fingerprint reading feature with the iPhone 5S. ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 31U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
Other Contents